Wells Fargo Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $50 to $55.
August 02, 2024 | 6:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) and raises the price target from $50 to $55.
The Overweight rating and increased price target from a reputable analyst at Wells Fargo is likely to boost investor confidence in Tandem Diabetes Care, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100